Ferrocene functionalized endocrine modulators as anticancer agents

Topics in Organometallic Chemistry

Volumn 32, Issue , 2010, Pages 81-117

  Hillard, Elizabeth A ^a   Vessières, Anne ^a   Jaouen, Gerard ^a  

^a PSL RESEARCH UNIVERSITY   (France)

Author keywords

Anti androgen; Anti oestrogen Anti oestrogenic; Breast cancer; Cytotoxic Cytotoxicity; Electrochemistry Electrochemical; Ferricenium; Ferrocene; Ferrocenophane; Hydroxyferrocifens; Hydroxytamoxifen (OH Tam); Oestradiol; Oestrogen receptor (ER); Oestrogen Oestrogenic; Phenol; Prostate cancer; Quinone; Raloxifen; RBA; ROS; Steroid; Tamoxifen; Testosterone; Vectorisation

Indexed keywords

EID: 77956705108     PISSN: 14366002     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-13185-1_4     Document Type: Article

References (180)

1. Wilkinson G, Rosenblum M, Whiting MC, Woodward RB (1952) The structure of iron bis-cyclopentadienyl. J Am Chem Soc 74:2125
2. Fischer EO, Pfab W (1952) Cyclopentadien-metallkomplexe, ein neuer typ metallorganischer verbidungen. Z Naturforsch 76:377-379
3. Yeary RA (1969) Chronic toxicity of dicyclopentadienyliron (ferrocene) in dogs. Toxicol Appl Pharmacol 15:666-676
4. Nesmeyanov AN, Bogomolova LG, Viltchevskaya V, Palitsyne N, Andrianova I, Belozerova O (1971) Ferrocerone. US Patent 119356
5. Loev B, Flores M (1961) Ferrocene derivatives. J Org Chem 26:3595-3595
6. Edwards EI, Epton R, Marr G (1975) Organometallic derivatives of penicillins and cephalosporins a new class of semi-synthetic antibiotics. J Organomet Chem 85:C23-C25
7. Edwards EI, Epton R, Marr G (1976) 1, 10-Ferrocenyldiacetic acid anhydride and its use in the preparation of heteroannularly substituted ferrocenyl-penicillins and -cephalosporins. J Organomet Chem 122:C49-C53
8. Biot C, Glorian G, Maciejewski LA, Brocard JS (1997) Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J Med Chem 40:3715-3718
9. Wu X, Tiekink ERT, Kostetski I, Kocherginsky N, Tan ALC, Khoo SB, Wilairat P, Go M-L (2006) Antiplasmodial activity of ferrocenyl chalcones: investigations into the role of ferrocene. Eur J Pharm Sci 27:175-187
10. Chantson JT, Varga Falzacappa MV, Crovella S, Metzler-Nolte N (2005) Antibacterial activities of ferrocenoyl- and cobaltocenium-peptide bioconjugates. J Organomet Chem 690:4564-4572
11. Chantson JT, Varga Falzacappa MV, Crovella S, Metzler-Nolte N (2006) Solid phase synthesis, characterisation and anti-bacterial activity of metallocene-peptide bioconjugates. ChemMedChem 1:1268-1274
12. Fiorina VJ, Dubois RJ, Brynes S (1978) Ferrocenyl polyamines as agents for chemoimmunotherapy of cancer. J Med Chem 21:393-395
13. Yashchenko GN, Shashmurina AA, Anoshina GM, Gorelova LA, Evstigneeva NG, Alekseeva LV, Radina LB (1978) Synthesis and study of the antineoplastic activity of ferrocene-containing compounds. Khim Farm Zh 12:68-72
14. Wenzel M, Schneider M, Liss E (1979) Z Naturforsch C 34:670-676
15. Köpf-Maier P, Köpf H, Neuse EW (1984) Ferrocenium salts- the first antineoplastic iron compounds. Angew Chem Int Ed Engl 23:456-457
16. Köpf-Maier P, Köpf H, Neuse EW (1984) Ferricenium complexes: a new type of watersoluble antitumor agent. J Cancer Res Clin Oncol 108:336-340
17. Neuse EW, Kanzawa F (1990) Evaluation of the activity of some water-soluble ferrocene and ferricinium compounds against carcinoma of the lung by the human tumor clonogenic assay. Appl Organomet Chem 4:19-26
18. Swarts JC, Neuse EW, Lamprecht GJ (1994) Synthesis and characterization of water-soluble polyaspartamide-ferrocene conjugates for biomedical applications. J Inorg Organomet Polym 4:143-153
19. Swarts JC, Swarts DM, Maree DM, Neuse EW, La Madeleine C, Van Lier JE (2001) Polyaspartamides as water-soluble carriers. Part 1: antineoplastic activivty of ferrocenecontaining polyaspartamide conjugates. Anticancer Res 21:2033-2037
20. Johnson MT, Kreft E, NDa DD, Neuse EW, van Rensburg CEJ (2003) The cytotoxic activity of macromolecular ferrocene conjugates against the Colo 320 DM human colon cancer line. J Inorg Organomet Polym 13:255-267
21. Caldwell G, Meirim MG, Neuse EW, van Rensburg CEJ (1998) Antineoplastic activity of polyaspartamide-ferrocene conjugates. Appl Organomet Chem 12:793-799
22. Ong CW, Jeng JY, Juang SS, Chen CF (1992) A ferrocene-intercalator conjugate with a potent cytotoxicity. Bioorg Med Chem Lett 2:929-932
23. Scarcia V, Furlani A, Longato B, Corain B, Pilloni G (1988) Heteropolymetallic complexes of 1, 10-bis(diphenylphosphino)ferrocene (dppf). IV. Solvolytic behavior and cytostatic properties towards the KB cell-line of dppf and 1, 2-bis(diphenylphosphino)ethane cis complexes of platinum(II) and palladium(II). Inorg Chim Acta 153:67-70
24. Hill DT, Girard GR, McCabe FL, Johnson RK, Stupik PD, Zhang JH, Reiff WM, Eggleston DS (1989) [mu-1, 10-bis(diphenylphosphino)ferrocene]bis(chlorogold): synthesis, iron-57 and gold-197 Moessbauer spectroscopy, X-ray crystal structure, and anti-tumor activity. Inorg Chem 28:3529-3533
25. Pilloni G, Graziani R, Longato B, Corain B (1991) Synthesis and the solution state of [the copper complex][(mu-dppf)(Cu(dppf))2]X2 (dppf 1, 10-bis-(diphenylphosphino)ferrocene; X ClO4-, BF4-). Inorg Chim Acta 190:165-167
26. Bincoletto C, Terariol ILS, Oliveira CR, Dreher S, Fausto DM, Soufen MA, Nascimento FD, Caires ACF (2005) Chiral cyclopalladated complexes derived from N, N-dimethyl- 1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathepsin B activity and as antitumoral agents. Bioorg Med Chem 13:3047-3055
27. Noor F, Kinscherf R, Bonaterra GA, Walczak S, Wölfl S, Metzler-Nolte N (2009) Enhanced cellular uptake and cytotoxicity studies of organometallic bioconjugates of the NLS peptide in Hep G2 cells. Chembiochem 10:493-502
28. Oparin DA, Makhaev VD, Vilchevskaya VD, Zimatkina TI, Motylevich ZV, Zimatkin SM, Zabrodskaya SV, Krylova AI, Gorelikova YY (1996) Synthesis and antitumor activity of vitamin B1 derivatives with a ferrocene fragment. Khim Farm Zh 30:11-13
29. Ferle-Vidovic A, Poljak-Blazi M, Rapic V, Skare D (2000) Ferrocenes (F168, F169) and fero-sorbitol-citrate (FSC): potential anticancer drugs. Cancer Biother Radiopharm 15:617-624
30. Hartinger CG, Nazarov AA, Arion VB, Giester G, Jakupec M, Galanski M, Keppler BK (2002) Novel glucose-ferrocenyl derivatives: synthesis and properties. New J Chem 26:671-673
31. Mooney A ́ , Corry AJ, OSullivan D, Rai DK, Kenny PTM (2009) The synthesis, structural characterization and in vitro anti-cancer activity of novel N-(3-ferrocenyl-2-naphthoyl) dipeptide ethyl esters and novel N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters. J Organomet Chem 694:886-894
32. Popova LV, Babin VN, Belousov YA, Nekrasov YS, Snegireva AE, Borodina NP, Shaposhnikova GM, Bychenko OB, Raevskii PM, Morozova NB, Iiyina AI, Shitkov KG (1993) Antitumor effects of binuclear ferrocene derivatives. Appl Organomet Chem 7:85-94
33. Neuse EW, Meirim MG, Blom NF (1988) Metallocene-containing platinum complexes as potential antitumor agents. 1. Dichloro(1, 6-differrocenyl-2, 5-diazahexane)platinum(II) and cis-dichlorobis(1-ferrocenylethylamine) platinum(II). Organometallics 7:2562-2565
34. Duivenvoorden WCM, Liu YN, Schatte G, Kraatz HB (2005) Synthesis of redox-active ferrocene pyrazole conjugates and their cytotoxicity in human mammary adenocarcinoma MCF-7 cells. Inorg Chim Acta 358:3183-3189
35. Von Poelhsitz G, Bogado AL, Peres de Araujo M, Selistre-de-Araujo HS, Ellena J, Castellano EE, Batista AA (2007) Synthesis, characterization, X-ray structure and preliminary in vitro antitumor activity of the nitrosyl complex fac-[RuCl3(NO)(dppf)], dppf 1, 10-bis(diphenylphosphine)ferrocene. Polyhedron 26:4707-4712
36. Kelly PN, Prêtre A, Devoy S, ORielly I, Devery R, Goel A, Gallagher JF, Lough AJ, Kenny PTM (2007) Synthesis, structural characterisation and biological activity of novel N-(ferrocenylmethyl)benzene-carboxamide derivatives J. Organomet Chem 692:1327-1331
37. Shago RF, Swarts JC, Kreft E, Van Rensburg CEJ (2007) Antineoplastic activity of a series of ferrocene-containing alcohols. Anticancer Res 27:3431-3434
38. Silva BV, Ribeiro NM, Pinto AC, Vargas MD, Dias LC (2008) Synthesis of ferrocenyl oxindole compounds with potential anticancer activity. J Braz Chem Soc 19:1244-1247
39. Swarts JC, Vosloo TG, Cronje SJ, Du Plessis WC, Van Rensburg CEJ, Kreft E, Van Lier JE (2008) Cytotoxicity of a series of ferrocene-containing beta.-diketones. Anticancer Res 28:2781-2784
40. Spencer J, Mendham AP, Kotha AK, Richardson SCW, Hillard EA, Jaouen G, Male L, Hursthouse MB (2009) Structural and biological investigation of ferrocene-substituted 3-methylidene-1, 3-dihydro-2H-indol-2-ones. Dalton Trans 6:918-921
41. Tamura H, Miwa M (1997) DNA cleaving activity and cytotoxic activity of ferricenium cations. Chem Lett 26(11):1177-1178
42. Osella D, Ferrali M, Zanello P, Laschi F, Fontani M, Nervi C, Cavigiolio G (2000) On the mechanism of the antitumor activity of ferrocenium derivatives. Inorg Chim Acta 306:42-48
43. Tabbi G, Cassino C, Cavigiolio G, Colangelo D, Ghiglia A, Viano I, Osella D (2002) Water stability and cytotoxic activity relationship of a series of ferricinium derivatives. ESR insights on the radical production during the degradation process. J Med Chem 45:5786-5796
44. Van Staveren DR, Metzler-Nolte N (2004) Bioorganometallic chemistry of ferrocene. Chem Rev 104:5931-5986
45. Fouda MFR, Abd-Elzaher MM, Abdelsamaia RA, Labib AA (2007) On the medicinal chemistry of ferrocene. Appl Organomet Chem 21:613-625
46. Jaouen G, Dyson P (2007) Medicinal organometallic chemistry. In: Crabtree RH, Mingos DMP (eds) Comprehensive organometallic chemistry III, vol 12. Elsevier, Oxford, pp 445-464
47. Metzler-Nolte N, Salmain M (2008) The bioorganometallic chemistry of ferrocene. In: Stepnicka P (ed) Ferrocenes: ligands, materials and biomolecules. Wiley, Chicester, pp 499-639
48. Meggers E (2009) Targeting proteins with metal complexes. Chem Commun 9:1001-1010
49. Gao W, Bohl CE, Dalton JT (2005) Chemistry and structural biology of androgen receptor. Chem Rev 105:3352-3370
50. Jordan VC (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 46:883-908
51. Newling DW (1996) Anti-androgens in the treatment of prostate cancer. Br J Urol 77:776-784
52. Reid P, Kantoff P, Oh W (1999) Antiandrogens in prostate cancer. Invest New Drugs 17:271-284
53. Jordan VC (1992) The role of tamoxifen in the treatment and prevention of breast cancer. Curr Probl Cancer 16:129-176
54. Raynaud JP, Bonne C, Moguilewsky M, Lefebvre FA, Belanger A, Labrie F (1984) The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. Prostate 5:299-311
55. Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G, Giuliani L (1991) Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 146:377-381
56. Neri R, Florance K, Koziol P, Van Cleave S (1972) A biological profile of a nonsteroidal antiandrogen, SCH 13521 (40-nitro- 30trifluoromethylisobutyranilide). Endocrinology 91:427-437
57. Neri R, Peets E, Watnick A (1979) Anti-androgenicity of flutamide and its metabolite SCH 16423. Biochem Soc Trans 7:565-569
58. Airhart RA, Barnett TF, Sullivan JW, Levine RL, Schlegel JU (1978) Flutamide therapy for carcinoma of the prostate. South Med J 71:798-801
59. Tucker H, Crook JW, Chesterson GJ (1988) Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J Med Chem 31:954-959
60. Top S, Tang J, Vessières A, Carrez D, Provot C, Jaouen G (1996) Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics. Chem Commun 8:955-956
61. Top S, Dauer B, Vaissermann J, Jaouen G (1997) Facile route to ferrocifen, 1-[4-(2-dimethylaminoethoxy)]- 1(phenyl-2-ferrocenyl-but-1-ene), first organometallic analogue of tamoxifen, by the McMurry reaction. J Organomet Chem 541:355-361
62. Jaouen G, Top S, Vessières A, Leclercq G, Quivy J, Jin L, Croisy A (2000) The first organometallic antioestrogens and their antiproliferative effects. C R Acad Sci Paris Ser IIc 3:89-93
63. Top S, Vessières A, Cabestaing C, Laios I, Leclercq G, Provot C, Jaouen G (2001) Studies on organometallic selective receptor modulators (SERMs). Dual activity in the hydroxy ferrocifen series. J Organomet Chem 637:500-506
64. Top S, Vessières A, Leclercq G, Quivy J, Tang J, Vaissermann J, Huché M, Jaouen G (2003) Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. Chem Eur J 9:5223-5236
65. Winkler VW, Nyman MA, Egan RS (1971) Diethylstilbestrol cis-trans isomerization and estrogen activity of diethylstilbestrol isomers. Steroids 17:197-207
66. Robertson DW, Katzenellenbogen JA (1982) Synthesis of the E and Z isomers of the antiestrogen tamoxifen and its metabolite, hydroxytamoxifen, in the tritium-labeled form. J Org Chem 47:2387-2393
67. Nguyen A, Top S, Pigeon P, Vessières A, Hillard EA, Plamont M-A, Huché M, Rigamonti C, Jaouen G (2009) Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains. Chem Eur J 15:684-696
68. Robertson DW, Katzenellenbogen JA, Hayes JR, Katzenellenbogen BS (1982) Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (2-) 1, 2-diph eny 1-1- [ 4- [2 - (dimet hy1amino)eth oxy ]p heny l]- 1- butene (Tamoxifen, Nolvadex) having altered basicity. J Med Chem 25:167-171
69. Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS (1982) Tamoxifen antiestrogens - a comparison of the activity, pharmacokinetics, and metabolic-activation of the cis-isomer and trans-isomer of tamoxifen. J Steroid Biochem 16:1-13
70. Bignon E, Pons M, Crastes de Paulet A, Doré JC, Gilbert J, Abecassis J, Miquel JF, Ojasoo T, Raynaud JP (1989) Effect of triphenylacrylonititrile derivatives on estradiol-receptor binding and on human breast cancer cell growth. J Med Chem 32:2092-2103
71. Coradini D, Biffi A, Cappelletti V, Fronzo GD (1994) Activity of tamoxifen and new antiestrogens on estrogen-receptor positive and negative breast-cancer cells. Anticancer Res 14:1059-1064
72. Van de Velde P, Nique F, Bouchoux F, Bremaud J, Hameau MC, Lucas D, Moratille C, Viet S, Philibert D, Teutsch G (1994) RU 58, 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J Steroid Biochem Mol Biol 48:187-196
73. Ang WH, Luca AD, Chapuis-Bernasconi C, Juillerat-Jeanneret L, Bello ML, Dyson PJ (2007) Organometallic ruthenium inhibitors of glutathione-s-transferase P1-1 as anticancer drugs. ChemMedChem 2:1799-1806
74. Vock CA, Ang WH, Scolaro C, Phillips AD, Lagopoulos L, Juillerat-Jeanneret L, Sava G, Scopelliti R, Dyson PJ (2007) Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem 50:2166-2175
75. Jakupec MA, Galanski M, Keppler BK (2003) Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev Physiol Biochem Pharmacol 146:1-53
76. Clemens JA, Bennett DR, Black LJ, Jones CD (1983) Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 32:2869-2875
77. Jordan VC (1995) Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem Suppl. 22:51-57
78. Willhite SL, Goebel SR, Scoggin JA (1998) Raloxifene provides an alternative for osteoporosis prevention. Ann Pharmacother 32:834-837
79. Ferreira AP, da Silva JLF, Duarte MT, da Piedade MFM, Robalo MP, Harjivan SG, Marzano C, Gandin V, Marques MM (2009) Synthesis and characterization of new organometallicbenzo[b]thiophene derivatives with potential antitumor properties. Organometallics 28:5412-5423
80. Osella D, Nervi C, Gaelotti F, Cavigiolio G, Vessières A, Jaouen G (2001) The ferrocenylethynyl unit: a stable hormone tag. Helv Chim Acta 84:3289-3298
81. Vessières A, Spera D, Top S, Misterkiewicz B, Heldt JM, Hillard EA, Huché M, Plamont MA, Napolitano E, Fiaschi R, Jaouen G (2006) The presence of a ferrocenyl unit on an estrogenic molecule is not always sufficient to generate in vitro cytotoxicity. ChemMed- Chem 1:1275-1281
82. Vessières A, Top S, Beck W, Hillard EA, Jaouen G (2006) Metal complex SERMs (Selective Estrogen Receptor Modulators). The influence of different metal units on breast cancer cell antiproliferative effects. Dalton Trans 4:529-541
83. Vessières A, Jaouen G, Gruselle M, Rossignol JL, Savignac M, Top S, Greenfield S (1988) Synthesis and receptor binding of polynuclear organometallic estradiol derivatives. J Steroid Biochem 30:301-306
84. Vessières A, Top S, Vaillant C, Osella D, Mornon JP, Jaouen G (1992) Estradiol modified by metal carbonyl clusters as suicide substrates for the study of receptor proteins: application to the estradiol receptor. Angew Chem Int Ed Engl 31:753-755
85. Top S, Vessières A, Jaouen G (1994) Synthetic strategy for organometallic complexes of rhenium with exceptionally high affinity for the estradiol receptor. Their potential use as imaging and therapeutic agents. J Chem Soc Chem Commun 4:453-454
86. Top S, El Hafa H, Vessières A, Huché M, Vaissermann J, Jaouen G (2002) Novel estradiol derivatives labeled with Ru, W, and Co complexes. Influence on hormone receptor affinity of several organometallic groups at the 17b position. Chem Eur J 8:5241-5249
87. Top S, Kaloun EB, Vessières A, Läos I, Leclercq G, Jaouen G (2002) The first titanocenyl dichloride moiety vectorised by a selective estrogen receptor modulator (SERM). Synthesis and preliminary biochemical behavior. J Organomet Chem 643-644:350-356
88. Top S, Masi S, Jaouen G (2002) The [Re(CO)6]+ cation as a ligand-transfer reagent with ferrocene derivatives. Eur J Inorg Chem 7:1848-1853
89. Top S, El Hafa H, Vessières A, Quivy J, Vaissermann J, Huges DW, McGlinchey MJ, Mornon JP, Thoreau E, Jaouen G (1995) Rhenium carbonyl complexes of b-estradiol derivatives with high affinity for the estradiol receptor: an approach to selective organometallic radiopharmaceuticals. J Am Chem Soc 117:8372-8380
90. El Amouri H, Vessières A, Vichard D, Top S, Gruselle M, Jaouen G (1992) Syntheses and affinities of novel organometallic-labeled estradiol derivatives: a structure-affinity relationship. J Med Chem 35:3130-3135
91. Foster AB, McCague R, Seago A, Leclercq G, Stoessel S, Roy F (1986) Modification of the basic side chain in tamoxifen: effects on microsomal metabolism and in vitro biological activity. Anticancer Drug Des 1:245-257
92. Jarman M, Leung OT, Leclercq G, Devleeschouwer N, Stoessel S, Coombes RC, Skilton RA (1986) Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts. Anticancer Drug Des 1:259-268
93. Magarian RA, Overacre LB, Singh S, Meyer KL (1994) The medicinal chemistry of nonsteroidal antiestrogens: a review. Curr Med Chem 1:61-104
94. Meegan MJ, Lloyd DG (2003) Advances in the science of estrogen receptor modulation. Curr Med Chem 10:181-210
95. Agouridas V, Laios I, Cleeren A, Kizilian E, Magnier E, Blazejewski J-C, Leclercq G (2006) Loss of antagonistic activity of tamoxifen by replacement of one N-methyl of its side chain by fluorinated residues. Bioorg Med Chem 14:7531-7538
96. Vessières A, Top S, Pigeon P, Hillard EA, Boubeker L, Spera D, Jaouen G (2005) Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro. J Med Chem 48:3937-3940
97. Mueller SO, Simon S, Chae K, Metzler M, Korach KS (2004) Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 80:14-25
98. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141:3657-3667
99. Gehm BD, Levenson AS, Liu H, Lee EJ, Amundsen BM, Cushman M, Jordan VC, Jameson JL (2004) Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wildtype estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol 88:223-234
100. Giusti RM, Iwamoto K, Hatch EE (1995) Diethylstilbestrol revisited: a review of the longterm health effects. Ann Intern Med 122:778-788
101. Schneider MR, Von Angerer E, Schönenberger H, Michel RT, Fortmeyer HP (1982) 1, 1, 2-triphenylbut-1-enes: relationship between structure, estradiol receptor affinity, and mammary tumor inhibiting properties. J Med Chem 25:1070-1077
102. Stoessel S, Leclercq G (1986) Competitive binding assay for estrogen receptor in monolayer culture: measure of receptor activity potency. J Steroid Biochem 25:677-682
103. Lubczyk H, Bachmann R, Gust R (2003) Antiestrogenically active 1, 1, 2-tris(4-hydroxyphenyl) alkenes without basic side chain: synthesis and biological activity. J Med Chem 46:1484-1491
104. Jaouen G, Top S, Vessières A (2006) In: Jaouen G (ed) Bioorganometallics. Wiley-VCH, Weinheim, pp 65-95
105. Hillard EA, Pigeon P, Vessières A, Amatore C, Jaouen G (2007) The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif. Dalton Trans 43:5073-5081
106. Hillard EA, Vessières A, Top S, Pigeon P, Kowalski K, Huché M, Jaouen G (2007) Organometallic diphenols: the importance of the organometallic moiety on the expression of a cytotoxic effect on breast cancer cells. J Organomet Chem 692:1315-1326
107. Shiina I, Sano Y, Nakata K, Kikuchi T, Sasaki A, Ikekita M, Nagahara Y, Hasome Y, Yamori T, Yamazaki K (2008) Synthesis and pharmacological evaluation of the novel pseudosymmetrical tamoxifen derivatives as anti-tumor agents. Biochem Pharmacol 75:1014-1026
108. Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL (2003) Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem Res Toxicol 16:832-837
109. Köpf-Maier P (1994) Complexes of metals other than platinum as antitumor agents. Eur J Clin Pharmacol 47:1-16
110. Guo M, Sun H, McArdle HJ, Gambling LK, Sadler PJ (2000) Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancel cells: understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry 39:10023-10033
111. Guo M, Guo Z, Sadler PJ (2001) Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride. J Biol Inorg Chem 6:698-707
112. Kröer K, Kleeberg UR, Mross K, Edler L, Hossfeld DK (2000) Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie 23:60-62
113. Mross K, Robben-Bathe P, Edler L, Baumgart J, Berdel WE, Fiebig H, Unger C (2000) Onkologie 23:576-579
114. Bläuenstein P (1990) Rhenium in nuclear medicine - general aspects and future goals. New J Chem 14:405-407
115. Alberto R (1996) High- and low-valency organometallic compounds of technetium and rhenium. Top Curr Chem 176:149-187
116. Top S, Vessières A, Pigeon P, Rager MN, Huché M, Salomon E, Cabestaing C, Vaissermann J, Jaouen G (2004) Selective estrogen receptor modulators (SERMs) in the cyclopentadienyl rhenium tricarbonyl series. Synthesis and Biological behaviour. Chembiochem 5:1104-1113
117. Jaouen G, Top S, Vessières A, Pigeon P, Leclercq G, Läos I (2001) First anti-oestrogen in the cyclopentadienyl rhenium tricarbonyl series. Synthesis and study of antiproliferative effects. Chem Commun 4:383-384
118. Schibli R, Alberto R, Petrig J, Ortner K, Schmalle H, Sigrist B, Stahel J, Scharzbach R, Schubiger PA (2001) J Labelled Comp Radiopharm 44:S723-S725
119. Wald J, Alberto R, Ortner K, Candreia L (2001) Aqueous one-pot synthesis of derivatized cyclopentadienyl-tricarbonyl complexes of 99mTc with an in situ CO source: application to a serotonergic receptor ligand. Angew Chem Int Ed Engl 40:3061-3066
120. Masi S, Top S, Boubeker L, Jaouen G, Mundwiler S, Spingler B, Alberto R (2004) Direct synthesis of tricarbonyl(cyclopentadienyl)rhenium and tricarbonyl(cyclopentadienyl)- technetium units from ferrocenyl moieties. Preparation of 17alpha-ethynylestradiol derivatives bearing a tricarbonyl(cyclopentadienyl)technetium group. Eur J Inorg Chem 10:2013-2017
121. Pigeon P, Top S, Vessières A, Huché M, Hillard EA, Salomon E, Jaouen G (2005) Selective estrogen receptor modulators (SERMs) in the Ruthenocene series. Synthesis and biological behavior. J Med Chem 48:2814-2821
122. Morris RE, Aird RE, Murdoch PS, Chen H, Cummings J, Hughes ND, Parsons S, Parkin A, Boyd G, Jodrell DI, Sadler PJ (2001) Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem 44:3616-3621
123. Allardyce CS, Dyson PJ, Ellis DJ, Heath SL (2001) Ru(n6-p-cymene)Cl2(pta) decane: a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem Commun 15:1396-1397
124. Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, Sadler PJ, Jodrell DI (2002) In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer 86:1652-1657
125. Galanski M, Arion VB, Jakupec MA, Keppler BK (2003) Curr Pharm Des 9:2078-2089
126. Alessio E, Mestroni G, Bergamo A, Sava G (2004) Ruthenium antimetastatic agents. Curr Top Med Chem 4:1525-1535
127. Taylor AJ, Wenzel M (1978) Fate of [RU-103]ruthenocene in mice and rats. Xenobiotica 8:107-112
128. Hillard EA, Vessières A, Le Bideau F, Plazuk D, Spera D, Huché M, Jaouen G (2006) A series of unconjugated ferrocenyl phenols: prospects as anticancer agents. ChemMedChem 1:551-559
129. Hillard EA, Vessières A, Thouin L, Jaouen G, Amatore C (2006) Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast cancer drug candidates. Angew Chem Int Ed Engl 45:285-290
130. Zekri O, Hillard EA, Top S, Vessières A, Pigeon P, Plamont M-A, Huché M, Boutamine S, McGlinchey MJ, Müller-Bunz H, Jaouen G (2009) Role of aromatic substituents on the antiproliferative effects of diphenyl ferrocenyl butene compounds. Dalton Trans 22:4318-4326
131. Pigeon P, Top S, Zekri O, Hillard EA, Vessières A, Plamont M-A, Labbé E, Buriez O, Huché M, Boutamine S, Amatore C, Jaouen G (2008) The replacement of a phenol group by an aniline or acetanilide group enhances the cytotoxicity of 2-ferrocenyl-1, 1-diphenyl-but-l-ene compounds against breast cancer cells. J Organomet Chem 694:895-901
132. Amrolia P, Sullivan SG, Stern A, Munday R (1989) Toxicity of aromatic thiols in the human red blood cell. J Appl Toxicol 9:113-118 (Pubitemid 19108624)
133. Burner U, Obinger C (1997) Transient-state and steady-state kinetics of the oxidation of aliphatic and aromatic thiols by horseradish peroxidase. FEBS Lett 411:269-274
134. Heilmann JB, Hillard EA, Plamont M-A, Pigeon P, Bolte M, Jaouen G, Vessières A (2008) Ferrocenyl compounds possessing protected phenol and thiophenol groups: synthesis, X-ray structure, and in vitro biological effects against breast cancer. J Organomet Chem 693:1716-1722
135. Katz J, Finlay TH, Banerjee S, Levitz M (1987) An estrogen-dependent esterase activity in MCF-7 cells. J Steroid Biochem 26:687-692
136. Katz J, Levitz M, Kadner SS, Finlay TH (1991) Estradiol esters can replace 17b-estradiol in the stimulation of DNA and esterase synthesis by MCF-7 cells: a possible role for the estrogen-sensitive MCF-7 cell esterase. J Steroid Biochem Mol Biol 38:17-26
137. Barnes KR, Kutikov A, Lippard SJ (2004) Synthesis, characterization, and cytotoxicity of a series of estrogen tethered platinum(IV) complexes. Chem Biol 11:557-564
138. Bartosz G (2006) Use of spectroscopic probes for detection of reactive oxygen species. Clin Chim Acta 368:53-76
139. Smith S, Pasco D, Pawlak J, Thompson B, Stampfer M, Nandi S (1984) Thioesterase II, a new marker enzyme for human cells of breast epithelial origin. J Natl Cancer Inst 73:323-329
140. Willson TM, Henke BR, Momtahen TM, Charifson PS, Batchelor KW, Lubahn DB, Moore LB, Oliver BB, Sauls HR, Triantafillou JA, Wolfe SG, Baer PG (1994) 3- [4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 37:1550-1552
141. Willson TM, Norris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S, Morris DC, McDonnell DP (1997) Endocrinology 138:3901
142. Kraft KS, Ruenitz PC, Bartlett MG (1999) Carboxylic acid analogues of tamoxifen: (Z)- 2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine. estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells. J Med Chem 42:3126-3133
143. Rubin VN, Ruenitz PC, Boudinot FD, Boyd JL (2001) Identification of new triarylethylene oxyalkanoic acid analogues as bone selective estrogen mimetics. Bioorg Med Chem 9:1579-1587
144. Wu Y-L, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL (2005) Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18:413-424
145. Nguyen A, Top S, Vessières A, Pigeon P, Huché M, Hillard EA, Jaouen G (2007) Organometallic analogues of tamoxifen: effect of the amino side-chain replacement by a carbonyl ferrocenyl moiety in hydroxytamoxifen. J Organomet Chem 692:1219-1225
146. Nguyen A, Marsaud V, Bouclier C, Top S, Vessières A, Pigeon P, Gref R, Legrand P, Jaouen G, Renoir J-M (2008) Nanoparticles loaded with ferrocenyl tamoxifen derivatives for breast cancer treatment. Int J Pharm 347:128-135
147. Plazuk D, Vessières A, Hillard EA, Buriez O, Labbé E, Pigeon P, Plamont M-A, Amatore C, Zakrzewski J, Jaouen G (2009) A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines. J Med Chem 52:4964-4967
148. Wlassoff WA, Albright CD, Sivashinski MS, Ivanova A, Appelbaum JG, Salganik RI (2007) Hydrogen peroxide overproduced in breast cancer cells can serve as an anticancer prodrug generating apoptosis-stimulating hydroxyl radicals under the effect of tamoxifen-ferrocene conjugate. J Pharm Pharmacol 59:1549
149. Osella D, Mahboobi H, Colangelo D, Cavigiolio G, Vessières A, Jaouen G (2005) FACS analysis of oxidative stress induced on tumour cells by SERMs. Inorg Chim Acta 358:1993-1998
150. Michard Q, Jaouen G, Vessières A, Bernard BA (2008) Evaluation of cytotoxic properties of organometallic ferrocifens on melanocytes, primary and metastatic melanoma cell lines. J Inorg Biochem 102:1980-1985
151. Fan PW, Zhang F, Bolton JL (2000) 4-hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem Res Toxicol 13:45-52
152. Schatzschneider U, Metzler-Nolte N (2006) New principles in medicinal organometallic chemistry. Angew Chem Int Ed Engl 45:1504-1507
153. Amatore C, Thiébault A, Verpeaux J-N (1989) Unexpected single electron-transfer catalyzed cyclization of prenyl sufore dimer - evidence for radical-anion coupling in the outer-sphere oxidation of prenyl sulfone carbanion. J Chem Soc Chem Commun 20:1543-1545
154. Amatore C, Bayachou M, Boutejengout F, Verpeaux J-N (1993) Evidences for the generation of alpha-alkoxy and alpha-alkyl thioalkyl radicals upon reduction of alpha-functionalized alkyl phenyl sufones - investigation of the reduction-mechanism by electrochemistry. Bull Soc Chim Fr 130:371-381
155. Schlesener CJ, Amatore C, Kochi JK (1984) Rates and mechanism of proton-transfer from trainsient carbon acids - the acidities of methylbenzene cations. J Am Chem Soc 106:7472-7482
156. Dehal SS, Kupfer D (1995) Cancer Res 56:1283-1290
157. Dasaradhi L, Shibutani S (1997) Identification of tamoxifen-DNA adducts formed by alphasulfate tamoxifen and alpha-acetoxytamoxifen. Chem Res Toxicol 10:189-196
158. Hardcastle IR, Horton MN, Osborne MR, Hewer A, Jarman M, Phillips DH (1998) Synthesis and DNA reactivity of alpha-hydroxylated metabolites of nonsteroidal antiestrogens. Chem Res Toxicol 11:369-374
159. Shibutani S, Dsaradhi L, Terashima I, Banoglu E, DuffelMW(1998)Alpha- hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res 58:647-653
160. Zhang F, Fan PW, Liu X, Shen L, van Breeman RB, Bolton JL (2000) Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen, 3, 4-dihydroxytamoxifeno- quinone. Chem Res Toxicol 13:53-62
161. Zanellato I, Heldt J-M, Vessières A, Jaouen G, Osella D (2009) Antiproliferative effect of ferrocifen drug candidates on malignant pleural mesothelioma cell lines. Inorg Chim Acta 362:4037-4042
162. Hamels D, Dansette P, Hillard EA, Top S, Vessières A, Herson P, Jaouen G, Mansuy D (2009) Ferrocenyl quinone methides as new strong antiproliferative agents: formation by metabolic and chemical oxidation of ferrocenyl phenols. Angew Chem Int Ed Engl 48:9124-9126
163. Buriez O, Labbé E, Pigeon P, Jaouen G, Amatore C (2008) Electrochemical attachment of a conjugated amino-ferrocifen complex onto carbon and metal surfaces. J Electroanal Chem 619-620:169-175
164. Nakayama J, Matsumaru N, Hoshino M (1981) Preparation of stable quinone methide imines. J Chem Soc Chem Commun 11:565-566
165. Huijzer JC, James D, Adams J, Yost GS (1987) Decreased pneumotoxicity of deuterated 3- methylindole: Bioactivation requires methyl C-H bond breakage. Tox Appl Pharm 90:60-68
166. Chow MM, Edgar F, Meyer J, Bode W, Kam C-M, Radhakrishnan R, Vijayalakshmi J, Powers JC (1990) The 2.2-A resolution X-ray crystal structure of the complex of trypsin inhibited by 4-chloro-3-ethoxy-7-guanidinoisocoumarin: a proposed model of the thrombininhibitor complex. J Am Chem Soc 112:7183-7189
167. Powers JC, Oleksyszyn J, Narasimhan SL, Kam C-M, Radhakrishnan REF, Meyer J (1990) Reaction of Porcine pancreatic elastase with 7-substituted 3-alkoxy-4-chloroisocoumarins: design of potent inhibitors using the crystal structure of the complex formed with 4-chloro-3- ethoxy-7-guanidinoisocoumarin. Biochemistry 29:3108-3118
168. Nocerini MR, Yost GS, Carlson JR, Liberato DJ, Breeze RG (1985) Structure of the glutathione adduct of activated 3-methylindole indicates that an imine methide is the electrophilic intermediate. Drug Metab Dispos 13:690-694
169. Charmantray F, Duflos A, Lhommea J, Demeunynck M (2001) Synthesis and study of 4-hydroxymethyl-3-(alkylamino)acridines as models of a new class of DNA-intercalating- alkylating agents. J Chem Soc 1:2962-2968
170. Powers JC, Kam C-M, Narasimhan L, Oleksyszyn J, Hernandez MA, Ueda T (2004) Mechanism-based isocoumarin inhibitors for serine proteases: use of active site structure and substrate specificity in inhibitor design. J Cell Biochem 39:33-46
171. Bose R, Ahmad AR, Dicks AP, Novak M, Kayser KJ, McClelland RA (1999) Spectroscopic characterization by laser flash photolysis of electrophilic intermediates derived from 4-aminostilbenes. Stilbene "nitrenium" ions and quinone methide imines. J Chem Soc Perkin I 2:1591-1599
172. Hitasome M, Watanabe J, Yamakawa K (1994) Selective oxidation of the a-methylene of the bridge in ferrocenophanes with silver oxide or silver perchlorate/sodium methoxide. Bull Chem Soc Jpn 67:280-283
173. Allard E, Passirani C, Garcion E, Pigeon P, Vessières A, Jaouen G, Benoit JP (2008) Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. J Control Release 130:146-153
174. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
175. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58:4497-4504 (Pubitemid 28480602)
176. Top S, Thibaudeau C, Vessières A, Brulé E, Bideau FL, Joerger J-M, Plamont M-A, Samreth S, Edgar A, Marrot J, Herson P, Jaouen G (2009) Synthesis and structure activity relationship of organometallic steroidal androgen derivatives. Organometallics 28:1414-1424
177. Jaouen G, Top S, Vessières A, Leclercq G, McGlinchey MJ (2004) The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. Curr Med Chem 11:2505-2517
178. Neuse EW (2005) Macromolecular ferrocene compounds as cancer drug models. J Inorg Organomet Polym Mater 15:3-32
179. Payen O, Top S, Vessieres A, Brule E, Plamont M, McGlinchey M, Muller-Bunz H, Jaouen G (2008) Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide. J Med Chem 51:1791-1799
180. http://www.sanofi-aventis.com/rd/Portfolio/p-rd-portfolio-medecine- interne.asp